LB Pharmaceuticals Inc Earnings Per Share (Diluted)
LB Pharmaceuticals Inc (LBRX) reported Earnings Per Share (Diluted) of -$1.71 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-11
- LB Pharmaceuticals Inc earnings per share, diluted for the quarter ending 2026-06-30 was -$1.71.
- LB Pharmaceuticals Inc earnings per share, diluted for the quarter ending 2026-03-31 was -$0.67.
- LB Pharmaceuticals Inc earnings per share, diluted for the quarter ending 2025-12-31 was -$0.45.
- LB Pharmaceuticals Inc earnings per share, diluted for the quarter ending 2025-09-30 was -$0.61.
- LB Pharmaceuticals Inc earnings per share, diluted for fiscal 2025 was -$3.13.
- LB Pharmaceuticals Inc earnings per share, diluted for fiscal 2024 was -$176.15.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.71 10-Q · filed 2026-08-11 | -$2.42 10-Q · filed 2026-08-11 | -$2.93 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.82 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.67 10-Q · filed 2026-05-12 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.71 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.60 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$0.96 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.13 10-K · filed 2026-03-26 |
| 2025-09-30 | -$0.61 10-Q · filed 2025-11-06 | -$2.73 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$6.26 10-Q · filed 2025-11-06 | -$10.93 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$13.58 10-Q · filed 2026-08-11 | -$28.36 10-Q · filed 2026-08-11 | -$42.48 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$81.98 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$14.79 10-Q · filed 2026-05-12 | -$28.90 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$68.40 derived: net income ÷ weighted average shares · filed 2026-08-11 | |
| 2024-12-31 | -$14.12 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$53.60 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$176.15 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$39.49 10-Q · filed 2025-11-06 | -$162.15 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |